Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chang Gung Memorial Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Histologically confirmed NSCLC, with at least one of the known oncogene mutation prior to systemic treatment: EGFR exon 18-21 activating mutation, MET exon-14-skipping mutation, ERBB2 activating mutation, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600 mutation, or KRAS G12C mutation
2. Patient had received tyrosine kinase inhibitor (TKI) with progressive disease, as assessed by the treating physician
3. Had tumor tissue available for DNA extraction and sequencing.
4. Eligible for withdrawal of a blood sample for DNA extraction and sequencing.
You may not be if
1. Patient had not received TKI or did not have documented disease progression during TKI treatment.
2. Tumor tissue was unavailable for DNA extraction or the DNA quality did not meet the sequencing requirement.
Clareo Health | Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
